Abstract: Microfluidic devices for analyzing cellular components from biological samples which contain more than one cell type are provided. The microdevice separates cells by type, releases cellular components such as DNA (e.g. by cell lysis) and processes the cellular components (for example, by amplification) to generate products of interest for further analysis. Samples that can be analyzed using the microfluidic devices include forensic samples such as samples from sexual assault victims, and the products of interest include short tandem repeat (STR) amplicons for DNA profiling.

Abstract: A system for determining the number of target nucleotide molecules in a sample includes a sample holder, an excitation optical system, an optical sensor, and an emission optical system. The sample holder is configured to receive an article comprising at least 20,000 separate reaction sites. The excitation optical system comprises a light source configured to simultaneously illuminate the at least 20,000 separate reaction sites. The optical sensor comprises a predetermined number of pixels, the predetermined number of pixels being at least 20 times the number of separate reaction sites. The emission optical system comprises a system working distance from the sample holder, wherein the working distance is less than or equal to 60 millimeters.

Abstract: The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising a blocking nucleic acid molecule represented by Formula IV, wherein Formula IV in the 5?-to-3? direction comprises: T-D-M-A-Lp-C; wherein T is 17-31 nucleotides in length; D is 0-15 nucleotides in length; M is 1-25 nucleotides in length; A is 0-15 nucleotides in length and comprises a sequence complementary to D; and L is 3-25 nucleotides in length; p is 0 or 1; C is 4-15 nucleotides in length and comprises a sequence complementary to T; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.

Abstract: The present invention pertains to the use of the calcium-sensing receptor (CaSR)-activating nutrients (designated as “CaSR-based nutrients”) for the prevention and/or treatment of diarrheal diseases and inflammation in the gastrointestinal tract. In one embodiment, the current invention is formulated for oral administration. The anti-diarrheal composition of the present invention is useful for treating diarrheal and gastrointestinal inflammatory conditions in infants and young children.

Abstract: A micronutrient composition shown as Mix 1 comprises Rosemary extract at 1 mg-6,000 mg, Fenugreek extract 1 mg-50,000 mg and Fenugreek seed powder at 2 mg-8,000 mg, Cassia nomane seed extract powder 1 mg to 1,000 mg and dry extract 1 mg-300 mg, 3?3-di indolylmethylene 1 mg-800 mg, Zinc 0.1 mg-1,000 mg, Phosphatidylserine 1 mg-1,500 mg, Vitamin D 20 IU-10,000 IU, Vitamin C 10 mg-50,000 mg, Niacin 1 mg-3,000 mg, Theanine 0.1 mg-10,000 mg, Aspartic acid 10 mg-10,000 mg, Arginine 10 mg-50,000 mg and Dehydroepiandrosterone (DHEA) 1 mg-500 mg and Mix A comprising of all the ingredients of Mix 1 but does not contain DHEA and both are used improve men's health.

Abstract: The invention relates to three-part makeup remover compositions comprising (a) a water part; (b) an oil part; and (c) a silicone-in-water emulsion part.

Abstract: Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

Abstract: This disclosure provides systems and methods for molecular identification and polymer (e.g., nucleic acid) sequencing using nanopores. The polymer may be passed through or in proximity to the nanopore and various subunits of the polymer may affect the current flowing through the nanopore. The various subunits may be identified by measuring the current at a plurality of voltages applied across the nanopore and/or membrane. In some cases, the polymerization of tagged nucleotides presents tag molecules to the nanopore that can be identified by measuring the current at a plurality of voltages applied across the nanopore and/or membrane. Also provided herein are systems and methods for sequencing both the sense and anti-sense strand of a double stranded nucleic acid molecule with a nanopore and methods for using ribonucleic acid (RNA) speed bump molecules to slow the passage of a nucleic acid molecule through or in proximity to a nanopore.

Abstract: A hair conditioner composition containing an aqueous carrier, from about 2.5 wt % to about 6.7 wt % of a behenamidopropyl dimethylamine, from about 3 wt % to about 8 wt % of a fatty alcohol; and less than 1.5 wt % of a salt. The molar ratio of behenamidopropyl dimethylamine to fatty alcohol can be from about 7:50 to about 4:5. The conditioner composition can have a uniform gel network. The composition can have d-spacing of less than 32 nm, as measured according to the d-spacing (L?-basal spacing) of Lamella Gel Network Test Method.

Abstract: A method of fabricating a device includes fabricating conductive surfaces including one or more capture surfaces and one or more reference surfaces, attaching a first molecular wire to each capture surface, and attaching a second molecular wire to each reference surface. The first and second molecular wires include chiral oligonucleotide multiplexes having identical nucleobase sequences and opposite absolute configuration. The first molecular wire includes a first oligonucleotide strand conjugated to a first functional handle including a sulfur-containing compound, and a second oligonucleotide strand conjugated to a capture agent that interacts with a target entity. The second molecular wire includes a first oligonucleotide strand conjugated to a second functional handle including a sulfur-containing compound, and a second oligonucleotide strand conjugated to a reference compound. The first and second oligonucleotide strands of each molecular wire are complementary and have the same absolute configuration.

Abstract: This invention provides biochip cartridges and instrument devices for the detection and/or analysis of target analytes from patient samples.

Abstract: A topical composition and method of treating chronic pain are provided. The topical composition contains cannabidiol (CBD) and plant extract and is well suited to treat chronic pain while also avoiding the negative side effects caused by commonly used anti-inflammatory and pain-treating compounds. When the topical composition is applied to the skin at the locus of pain and allowed sufficient time to absorb, the pain is reduced or even eliminated. The topical compositions also show therapeutic effect on mucosal tissue and internal tissues of humans or animals.

Abstract: An array includes a support including a plurality of discrete wells, a gel material positioned in each of the plurality of discrete wells, and a quality control tracer grafted to the gel material in each of the plurality of discrete wells. The quality control tracer comprises (a) a cleavable nucleotide sequence comprising a cleavage site and (b) a detectable label; and in some aspects, is a cleavable nucleotide sequence with a detectable label and a non-reactive nucleotide sequence or a primer nucleotide sequence.

Abstract: Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.

Abstract: A personal cleansing soap bar composition is provided, comprising: a soap; an aqueous ethylene acrylic acid copolymer dispersion; a silicone copolymer emulsion with an internal phase viscosity at 25° C. of ?100×106 mm2/sec; wherein the personal cleansing soap bar is a solid.

Abstract: An ethyl 2-[9-(6-fluoro-2-hydroxyquinolin-3-yl)-1,8-dioxo-3,4,9,10-tetrahydroacridine-10-yl]-acetate compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A simple cellulose sulphate based microencapsulation technology has been applied to encapsulate bacterial or other microbial cells, which produce and release digestive enzymes and thereby provides an acid resistant shelter for these microbial cells. Surprisingly, the resulting spheres were found to provide sufficient protection for encapsulated cells from treatment with aqueous acidic solutions. Thereby the cellulose sulphate microencapsulated cells, such as probiotics are now enabled to survive passage, for example, through the stomach after consumption by a human or animal with a higher survival rate than those not within a microcapsule. After passing the stomach these cells are delivering products produced by them, e.g. enzymes or other nutrition factors. This technology therefore proves to be very useful in providing digestive or otherwise beneficial enzymes and/or of living microbial cells, into the lower gastrointestinal tract, where they could confer their health benefit to the host.

Abstract: The present disclosure provides use of fructose in preparing a drug for treating a cerebral ischemic stroke, and relates to the technical field of biomedicine. In the present disclosure, an ischemic injury cell model and an ischemic injury animal model are established, and fructose treatment is conducted on the injury models; and it is found that the fructose can regulate energy metabolism and redox metabolism of neurons, and reduce an ischemic injury of model cells and model animals. Specifically, the present disclosure includes: reducing a neuronal mortality after the ischemic injury, reducing an area of cerebral infarction in animals with the ischemic injury, and improving neurobehavioral characteristics of the animals.

Abstract: A hair conditioner composition containing an aqueous carrier, a cationic surfactant, a high melting point fatty compound and an effective preservation system. The conditioner composition comprises a gel network. The preservation system contains sodium benzoate and a second composition selected from the group consisting of glycol, glyceryl ester, and combinations thereof.

Abstract: Disclosed in the present specification is a liquid lipid composite composition comprising ceramide, cholesterol, a C10-30 unsaturated fatty acid having three or fewer double bonds, and natural oil or wax containing a C10-60 fatty acid ester or C10-60 fatty acid ester at a weight ratio of 1:0.03-3:2.5-12:0.3-6. The liquid lipid composite composition comprises a high content of ceramide and is present in a liquid state during storage at normal temperature, and thus can be easily applied as a formulation of a hair cosmetic composition. The liquid lipid composite composition, when used to treat hair, has excellent hair condition improving effects, such as improving the softness of the hair, enhancing the elasticity and strength of the hair, and increasing the shininess of the hair.